Drug Trial News

RSS

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, the independent Data Monitoring Committee recommended suspension of enrollment.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

Investigational drug effective for patients with obesity

An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers at Duke University Medical Center.

11 Apr 2011

New study finds no significant benefit of bosentan against IPF

A new study has demonstrated no significant benefit of taking the drug bosentan for idiopathic pulmonary fibrosis.

11 Apr 2011

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris Group announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.

8 Apr 2011

FDA grants tentative approval for Hi-Tech Pharmacal's generic Combigan ANDA

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.

8 Apr 2011

ViroXis' IND for EISO-derived product to treat HPV skin warts receives FDA approval

ViroXis Corporation today announced that the US Food and Drug Administration (FDA) granted approval for the Company's investigational new drug (IND) application and planned clinical development of a drug substance derived from East Indian Sandalwood oil (EISO) for the topical treatment of Human Papilloma Virus (HPV), common warts of the skin.

8 Apr 2011

HALT-C trial reveals high mortality rates among patients with HCV

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis.

8 Apr 2011

Long-term delivery of CNTF slows loss of visual acuity caused by geographic atrophy

A phase 2 clinical trial for the treatment of a severe form of age-related macular degeneration called geographic atrophy (GA) has become the first study to show the benefit of a therapy to slow the progression of vision loss for this disease. The results highlight the benefit of the use of a neurotrophic factor to treat GA and provide hope to nearly one million Americans suffering from GA.

8 Apr 2011

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye, an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema.

8 Apr 2011

Targacept's TC-5619 Phase 2 trial data in schizophrenia presented at ICOSR

Targacept, Inc. today announced the presentation of data from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia at the International Congress on Schizophrenia Research in Colorado Springs, Colorado.

8 Apr 2011

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

8 Apr 2011

Positive top-line results from Roche's T-DM1 Phase II trial in HER2-positive MBC

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine in HER2-positive metastatic breast cancer.

7 Apr 2011

MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal

MAP Pharmaceuticals, Inc. today announced the publication of results from the Phase 3 FREEDOM-301 study of LEVADEX orally inhaled migraine drug in the peer-reviewed journal 'Headache.'

7 Apr 2011

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Neuralstem, Inc. announced that the Phase I safety trial of its human spinal cord stem cells in amyotrophic lateral sclerosis is the subject of three presentations at the American Academy of Neurology Annual Meeting, April 9-16th, in Honolulu, HI.

7 Apr 2011

OncoGenex, Teva's custirsen preclinical data in CRPC presented at AACR meeting

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that new preclinical data of their investigational compound custirsen in castrate resistant prostate cancer were presented this week at the 102nd Annual Meeting of the AACR.

7 Apr 2011

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics, Inc. today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation Annual Meeting in Paris, France.

7 Apr 2011

Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal

Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced the publication of Phase III PROCHIEVE® (progesterone gel) data in today's online version of Ultrasound in Obstetrics & Gynecology, the leading peer-reviewed journal of the International Society of Ultrasound in Obstetrics & Gynecology.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced that it has successfully completed two Phase 1a clinical studies for AVL-292, its orally-available, selective inhibitor of Bruton's tyrosine kinase (Btk).

6 Apr 2011

Drug Trial News

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Gilenya can reduce risk of disability progression in patients with RRMS

Investigational drug effective for patients with obesity

New study finds no significant benefit of bosentan against IPF

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

FDA grants tentative approval for Hi-Tech Pharmacal's generic Combigan ANDA

ViroXis' IND for EISO-derived product to treat HPV skin warts receives FDA approval

HALT-C trial reveals high mortality rates among patients with HCV

Long-term delivery of CNTF slows loss of visual acuity caused by geographic atrophy

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Targacept's TC-5619 Phase 2 trial data in schizophrenia presented at ICOSR

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Positive top-line results from Roche's T-DM1 Phase II trial in HER2-positive MBC

MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

OncoGenex, Teva's custirsen preclinical data in CRPC presented at AACR meeting

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News